BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-07-01 pm EDT
251.80 USD   +2.14%
06/30Becton, Dickinson Unveils Combination Assay for COVID-19, Other Respiratory Viruses
MT
06/30BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus
PR
06/30Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity

05/16/2022 | 08:09am EDT

FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it has been named a 'Noteworthy Company' for the third straight year in DiversityInc's annual ranking of the top U.S. companies for diversity.

Since 2001, the DiversityInc survey has been the most comprehensive, empirically data-driven diversity and inclusion analysis based on organization-submitted information from the largest U.S. employers. The assessment collects data across six key areas: leadership accountability, human capital diversity metrics, talent programs, workplace practices, supplier diversity and philanthropy.

'An inclusive environment and diverse workforce produces better outcomes for customers and patients, and is core to our purpose of advancing the world of health for all,' said Nicole Thompson, vice president of HR - Inclusion, Diversity, Equity & Engagement at BD. 'We will continue to accelerate our progress to further empower our associates to thrive personally and professionally, and make a difference in our communities.'

This year BD was also recognized by Forbes as one of the top employers in the U.S. for diversity, included in the 2022 Bloomberg Gender-Equality Index, and named a Best Place to Work for LGBTQ+ Equality by The Human Rights Campaign Foundation after receiving a perfect score (100%) on the organization's Corporate Equality Index.

These recognitions demonstrate the company's ongoing progress in advancing its environmental, social and governance (ESG) strategy, and efforts to achieve its 2030+ goals for promoting a healthy workforce and communities. These goals encompass maintaining a healthy and thriving workforce that cultivates the company's culture of inclusion, safety, well-being, and also contributes to community and company health.

To learn more about the inclusion, diversity and equity systems, processes and tools that drive action and accountability at BD, read the 2021 Global ID&E Report.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contact:

Media

Troy Kirkpatrick

VP

Public Relations

T: 858.617.2361

E: troy.kirkpatrick@bd.com

Investors

Francesca DeMartino

SVP

Head of Investor Relations

T: 201.847.5743

E: francesca.demartino@bd.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about BECTON, DICKINSON AND COMPANY
06/30Becton, Dickinson Unveils Combination Assay for COVID-19, Other Respiratory Viruses
MT
06/30BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Viru..
PR
06/30Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and..
CI
06/29BD - Harris Poll Survey Reveals Clinicians Continue to See COVID-19 Testing as Critical
AQ
06/24Wells Fargo Upgrades Becton Dickinson and Co. to Overweight From Equalweight; Price Tar..
MT
06/23Becton, Dickinson and Company Recalls Intraosseous Products
MT
06/22BD Voluntarily Recalling Intraosseous Products
DJ
06/22BD Announces Voluntary Recall on Intraosseous Products
CI
06/22Eastern Health and BD Implement Innovative Solution with Goal of Reducing Consumption o..
AQ
06/22Eastern Health and Becton, Dickinson and Company Implement Innovative Solution with Goa..
CI
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 678 M - -
Net income 2022 1 770 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 38,7x
Yield 2022 1,51%
Capitalization 71 779 M 71 779 M -
EV / Sales 2022 4,56x
EV / Sales 2023 4,31x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 251,80 $
Average target price 280,50 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.45%71 779
ABBOTT LABORATORIES-21.69%192 989
MEDTRONIC PLC-11.67%121 417
BAXTER INTERNATIONAL INC.-23.71%32 976
HOYA CORPORATION-32.14%31 045
DEXCOM, INC.-42.17%30 470